Description
Taylor & Francis Protease Inhibitors in AIDS Therapy 2001 Edition by Richard C. Ogden, Charles Flexner
Details the evolution of HIV protease inhibitors from molecular development through medical applications!Considering the latest class of revolutionary drugs fighting against HIV infection and AIDS, this comprehensive reference thoroughly examines the development and properties of HIV protease inhibitors from clinical and scientific perspectives, discussing how protease inhibitors changed the FDA approval process-enhancing the collaboration between regulatory authorities and drug developers.Spotlights protease inhibitors as the cornerstone drugs of the first HAART regimens-key components of long-term viral suppression and immune restoration, and in secondary and tertiary regimens!Evaluating protease inhibitors as therapeutic options and research tools, Protease Inhibitors in AIDS Therapy reviews the impact of advances in recombinant DNA technology for understanding and treating HIV and AIDS highlights a variety of strategies and techniques for drug discovery and development illustrated by success stories of pharmaceutical companies and biotechnology start-up firms summarizes the pharmacokinetics, metabolism, and drug interactions of protease inhibitors details preliminary clinical studies on oral bioavailability, pharmacokinetic profiling, efficacy, resistance, and tolerability describes available efficacy data for marketed inhibitors and those in clinical development reports on efforts to manage antiviral resistance in the clinic and improve patient adherence to complex drug therapy and more!Containing more than 600 helpful literature references, drawings, photographs, and tables, Protease Inhibitors in AIDS Therapy serves for an essential reference for infectious disease specialists, epidemiologists, virologists, immunologists, pharmacologists, medicinal chemists and biochemists, microbiologists, hematologists, hepatologists, and medical students in these disciplines. Table of contents :- Foreword,John G. Bartlett, The Johns Hopkins University School of Medicine, Baltimore, MarylandHIV-1 Protease as a Target for AIDS Therapy,John W. EricksonDiscovery and Early Development of Saquinavir,Ian B. Duncan and Sally RedshawDiscovery and Early Development of Ritonavir and ABT-378,Dale J. KempDiscovery and Early Development of Indinavir,Bruce D. Dorsey and Joseph P. VaccaDiscovery and Development of Nelfinavir (Viracept),Siegfriend H. ReichDesign and Synthesis of Amprenavir, A Novel HIV Protease Inhibitor,R. D. Tung, D. J. Livingston, B. G. Rao, E. E. Kim, C. T. Baker, J. S. Boger, S. P. Chambers, D. D. Delhinger, M. Dwyer, L. Elsayed, J. Fulghum, B. Li, M. A. Murcko, M. A. Navia, P. Novak, S. Pazhanisamy, C. Stuver, and J.A. ThomsonHIV Protease Inhibitors in Early Development,R. Alan Chrusciel, Judith A. Nicholas, and Suvit ThaisrivongsPharmacology and Drug Interactions of HIV Protease Inhibitors,Charles W. FlexnerBeneficial Pharmokinetic Interactions: Are Two Protease Inhibitors Better than One?,Charles W. FlexnerProtease Inhibitors: Clinical Efficacy,Roy M. GulickToxicities and Adverse Effects of Protease Inhibitors,Marshall J. GlesbyResistance to HIV-1 Protease Inhibitors,Benjamin Young and Daniel R. KuritzkesExpedited Drug Approval and HIV Protease Inhibitors,Jeff MurrayUse of Protease Inhibitors in the Management of HIV/AIDS,Richard C. Ogden and Charles W. Flexner